The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients

Cardiovascular Therapeutics

Volumn 34, Issue 3, 2016, Pages 144-151

  Koektuerk, Buelent ^a   Turan, Cem H ^a   Yorgun, Hikmet ^a   Keskin, Kerim ^a   Schoett, Moritz ^a   Dahmen, Alina ^a   Gorr, Eduard ^a   Yang, Alexander ^a   Hoppe, Christian ^a   Horlitz, Marc ^a   Turan, Ramazan G ^a,b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Atrial fibrillation; Complications; Cryoballoon ablation; Novel oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; C REACTIVE PROTEIN; DABIGATRAN; RIVAROXABAN; AUTACOID; BIOLOGICAL MARKER; PHENPROCOUMON; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ABLATION THERAPY; ADULT; ADVERSE OUTCOME; ARTERIOVENOUS FISTULA; ARTICLE; ATRIAL FIBRILLATION; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CRYOABLATION; CRYOBALLOON ABLATION; FALSE ANEURYSM; FEMALE; HEART TAMPONADE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; VISUAL IMPAIRMENT; ADVERSE EFFECTS; AGED; BLOOD; COMPARATIVE STUDY; CRYOSURGERY; DEVICES; GERMANY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PULMONARY VEIN; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOMARKERS; CRYOSURGERY; DABIGATRAN; FEMALE; GERMANY; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PHENPROCOUMON; POSTOPERATIVE COMPLICATIONS; PULMONARY VEINS; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RIVAROXABAN; TREATMENT OUTCOME;

EID: 84969857908     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12178     Document Type: Article

References (31)

1. Metzner A, Reissmann B, Rausch P, et al. One-year clinical outcome after pulmonary vein isolation using the second-generation 28-mm cryoballoon. Circ Arrhythm Electrophysiol 2014;7:288-292.
2. Metzner A, Heeger CH, Wohlmuth P, et al. Two-year outcome after pulmonary vein isolation using the second-generation 28-mm cryoballoon: Lessons from the bonus freeze protocol. Clin Res Cardiol 2016;105:72-78.
3. Mikhaylov EN, Lebedev DS, Pokushalov EA, et al. Outcomes of cryoballoon ablation in high- and low-volume atrial fibrillation ablation centres: A Russian Pilot Survey. Biomed Res Int 2015;2015:591603.
4. Aryana A, Singh SM, Kowalski M, et al. Acute and long-term outcomes of catheter ablation of atrial fibrillation using the second-generation cryoballoon versus open-irrigated radiofrequency: A multicenter experience. J Cardiovasc Electrophysiol 2015;26:832-839.
5. Aytemir K, Gurses KM, Yalcin MU, et al. Safety and efficacy outcomes in patients undergoing pulmonary vein isolation with second-generation cryoballoondagger. Europace 2015;17:379-387.
6. Ciconte G, Ottaviano L, de Asmundis C, et al. Pulmonary vein isolation as index procedure for persistent atrial fibrillation: One-year clinical outcome after ablation using the second-generation cryoballoon. Heart Rhythm 2015;12:60-66.
7. Koektuerk B, Yorgun H, Hengeoez O, et al. Cryoballoon ablation for pulmonary vein isolation in patients with persistent atrial fibrillation: One-year outcome using second generation cryoballoon. Circ Arrhythm Electrophysiol 2015;8:1073-1079.
8. Mugnai G, de Asmundis C, Ciconte G, et al. Incidence and characteristics of complications in the setting of second-generation cryoballoon ablation: A large single-center study of 500 consecutive patients. Heart Rhythm 2015;12:1476-1482.
9. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-1413.
10. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The Task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-1420.
11. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528-606.
12. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm 2012;9:632-696. e21.
13. Pandya B, Sheikh A, Spagnola J, et al. Safety and efficacy of second-generation versus first-generation cryoballoons for treatment of atrial fibrillation: A meta-analysis of current evidence. J Interv Card Electrophysiol 2016;45:49-56.
14. Aytemir K, Canpolat U, Yorgun H, et al. Usefulness of 'figure-of-eight' suture to achieve haemostasis after removal of 15-French calibre femoral venous sheath in patients undergoing cryoablation. Europace 2015; doi: 10.1093/europace/euv375 [Epub ahead of print]
15. Gurses KM, Kocyigit D, Yalcin MU, et al. Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation. J Interv Card Electrophysiol 2015;43:161-167.
16. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32-38.
17. Straube F, Dorwarth U, Ammar-Busch S, et al. First-line catheter ablation of paroxysmal atrial fibrillation: Outcome of radiofrequency vs. cryoballoon pulmonary vein isolation. Europace 2015; doi: 10.1093/europace/euv271 [Epub ahead of print]
18. Schmidt M, Dorwarth U, Andresen D, et al. German ablation registry: Cryoballoon versus RF ablation in paroxysmal atrial fibrillation - one year outcome data. Heart Rhythm 2015; doi: 10.1016/j.hrthm.2015.12.007 [Epub ahead of print]
19. Snipelisky D, Ray JC, Ung R, et al. A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. J Interv Card Electrophysiol 2014;41:231-236.
20. Garton AB, Dudzinski J, Kowey PR. Oral anticoagulant use around the time of atrial fibrillation ablation: A review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis. J Cardiovasc Electrophysiol 2014;25:1411-1418.
21. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129:2638-2644.
22. Rillig A, Lin T, Plesman J, et al. Apixaban, rivaroxaban and dabigatran in patients undergoing atrial fibrillation ablation. J Cardiovasc Electrophysiol 2015;27:147-153.
23. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2012;59:1168-1174.
24. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013;10:483-489.
25. Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013;36:172-179.
26. Wissner E, Heeger CH, Grahn H, et al. One-year clinical success of a 'no-bonus' freeze protocol using the second-generation 28 mm cryoballoon for pulmonary vein isolation. Europace 2015;17:1236-1240.
27. Tebbenjohanns J, Hofer C, Bergmann L, et al. Shortening of freezing cycles provides equal outcome to standard ablation procedure using second-generation 28 mm cryoballoon after 15-month follow-up. Europace 2015; doi: 10.1093/europace/euv189 [Epub ahead of print]
28. Ciconte G, Mugnai G, Sieira J, et al. On the quest for the best freeze: Predictors of late pulmonary vein reconnections after second-generation cryoballoon ablation. Circ Arrhythm Electrophysiol 2015;8:1359-1365.
29. Toner M, Cravalho EG, Ernest G, et al. Thermodynamics and kinetics of intracellular ice formation during freezing of biological cells. J Appl Phys 1990;67:1582-1593.
30. Avitall B, Kalinski A. Cryotherapy of cardiac arrhythmia: From basic science to the bedside. Heart Rhythm 2015;12:2195-2203.
31. Wojcik M, Berkowitsch A, Greis H, et al. Learning curve in cryoballoon ablation of atrial fibrillation: Eight-year experience. Circ J 2014;78:1612-1618.